Product Description
XALKORI® (crizotinib) is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1. (Sourced from: https://www.xalkori.com/)
Mechanisms of Action: ALK Inhibitor,TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, France, Germany, Israel, Italy, Japan, Korea, Netherlands, Poland, Russia, South Korea, Spain, Switzerland, Thailand, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 12
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Uveal Melanoma
Phase 2: Alveolar Rhabdomyosarcoma|Alveolar Soft Part Sarcoma|Clear Cell Sarcoma|Gastrointestinal Cancer|Large Cell Carcinoma|Lobular Carcinoma|Lymphoma|Papillary Carcinoma|Renal Cell Carcinoma|Squamous Cell Carcinoma|Triple Negative Breast Cancer
Phase 1: Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IDE196-002 | P3 |
Unknown Status |
Uveal Melanoma |
2027-12-31 |
|
| IDE196-002 | P3 |
Unknown Status |
Uveal Melanoma |
2027-12-31 |
|
| DAR-UM-2 | P3 |
Recruiting |
Uveal Melanoma |
2027-01-15 |
|
| TGRX-326-3001-NSCLC-CN | P3 |
Recruiting |
Non-Small-Cell Lung Cancer |
2024-12-31 |